Will ZIOPHARM Oncology (ZIOP) Stock Decline After Analyst Downgrade?

NEW YORK (TheStreet) -- Shares of ZIOPHARM Oncology Inc  were up 0.41% to $12.19 in mid-morning trading Monday, despite getting a rating cut by analysts at BMO Capital earlier this morning. The firm downgraded shares of the biotechnology company to "market perform" from "outperform" on a valuation call. BMO analysts lowered its price target to $10 from $15, adding that they believe the company has fallen further behind its competitors. Boston-based ZIOPHARM Oncology is a biotechnology company ...